Next Article in Journal
Short-Term Dietary Intervention with Cooked but Not Raw Brassica Leafy Vegetables Increases Telomerase Activity in CD8+ Lymphocytes in a Randomized Human Trial
Next Article in Special Issue
Probiotics in Extraintestinal Diseases: Current Trends and New Directions
Previous Article in Journal
Consumption Patterns of Grain-Based Foods among Adults in Canada: Evidence from Canadian Community Health Survey—Nutrition 2015
Previous Article in Special Issue
Exopolysaccharide-Producing Bifidobacterium adolescentis Strains with Similar Adhesion Property Induce Differential Regulation of Inflammatory Immune Response in Treg/Th17 Axis of DSS-Colitis Mice
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle
Nutrients 2019, 11(4), 785;

Lactobacillus fermentum PC1 has the Capacity to Attenuate Joint Inflammation in Collagen-Induced Arthritis in DBA/1 Mice

Centre for Marine Bio-Innovation, School of Biological, Earth and Environmental Sciences, The University of New South Wales, Sydney, NSW 2052, Australia
NTU Food Technology Centre (NAFTEC), School of Chemical and Biomedical Engineering, Nanyang Technology University, 637459 Singapore, Singapore
Author to whom correspondence should be addressed.
Received: 5 March 2019 / Revised: 29 March 2019 / Accepted: 1 April 2019 / Published: 5 April 2019
(This article belongs to the Special Issue Health Benefits of Traditional and Next Generation Probiotics)
PDF [1668 KB, uploaded 5 April 2019]


Lactobacillus strains have shown efficacy in attenuating inflammation. This study evaluated the potential of Lactobacillus fermentum PC1 for the treatment of rheumatoid arthritis (RA) using a murine model of collagen-induced arthritis. On Day 1, healthy DBA/1 mice (six to eight weeks of age) were immunized, with 100 μg of Chicken Type 11 collagen emulsified in complete Freund’s adjuvant (CFA) by intradermal injection, at the base of the tail. On Day 21, the mice were immunized intraperitoneally with 100 μg of Bovine Type11 collagen in phosphate buffered saline (PBS). On Day 28, the mice were immunized intraperitoneally with 50 μg of lipopolysaccharide (LPS). Viable L. fermentum PC1 (1 × 109 colony forming units) was given daily from Day two until the end of the experiment. From Day 21 onwards, the mice were monitored daily for clinical signs of arthritis. On Day 44, the experiment was terminated. Paws were obtained for histology and serum for cytokine assays. L. fermentum PC1-fed mice had significantly reduced paw inflammation as well as decreased synovial infiltration and less cartilage damage. Circulating serum cytokine profiles revealed decreased IL-12 and increased anti-inflammatory cytokines, namely IL-4 and IL-10. Thus, early administration of L. fermentum PC1 could prove to be a valuable therapeutic agent in the management of RA. View Full-Text
Keywords: L. fermentum PC1; Collagen induced arthritis; inflammation L. fermentum PC1; Collagen induced arthritis; inflammation

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Esvaran, M.; Conway, P.L. Lactobacillus fermentum PC1 has the Capacity to Attenuate Joint Inflammation in Collagen-Induced Arthritis in DBA/1 Mice. Nutrients 2019, 11, 785.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top